← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue rose 44.7% to $65.18B and net income 94.9% to $20.64B, driven by Mounjaro and Zepbound.
The read at a glance✓ Audited against SEC data
- Growth — Revenue +44.7% to $65.18B on higher volumeOK
- Profitability — Net income $20.64B; net margin 31.7%, up 816 bpsOK
- Cash — Operating cash flow $16.81B, +90.7%OK
- Balance sheet — Long-term debt $40.87B, +38.7%Watch
- Accounting — Safe-zone Altman-Z; no manipulation flag; earnings quality greyNote
- Concentration — Mounjaro and Zepbound: $36,507m of $65,179m revenueWatch
Business
Eli Lilly discovers, makes and sells medicines. Its growth now comes from tirzepatide, sold as Mounjaro and, for obesity in Canada, Japan and the U.S., as Zepbound. Together the two brands brought in $36,507m of its $65,179m revenue in 2025.
Where the revenue comes from
Fiscal 2025, as ELI LILLY & Co reports it. History and quarterly detail are in the app.
- Net product revenue$61.0B
- Cardiometabolic Health$48.2B
- Oncology$9.4B
- Immunology$5.2B
- Collaboration and Other Revenue$4.2B
Leadership changes
From ELI LILLY & Co's own filings, the day they're filed.
- Carolyn R. Bertozzi · Directors · appointmenteff. 2025-12-08
- Karen Walker · Chief Executive Officer · departureeff. 2024-12-01
- Lucas Montarce · chief financial officer · appointmenteff. 2024-09-09
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-05-20
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ELI LILLY & Co, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.